Innovent Biologics Inc
F:6IB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Innovent Biologics Inc
F:6IB
|
CN |
|
C
|
Corestate Capital Holding SA
DUS:CCAP
|
LU |
|
K
|
Kaneka Corp
XMUN:KKA
|
JP |
|
V-cube Inc
F:VCU
|
JP |
|
IT Link SA
F:IL8
|
FR |
|
B
|
Biofrontera AG
XMUN:B8F
|
DE |
|
Modec Inc
OTC:MDIKF
|
JP |
|
T
|
TruFin PLC
F:29U
|
UK |
|
Cruz Battery Metals Corp
F:BR00
|
CA |
|
Team Internet Group PLC
F:4CN
|
UK |
|
C
|
CASI Pharmaceuticals Inc
F:ENMN
|
US |
|
B
|
Biofrontera AG
SWB:B8F
|
DE |
|
A
|
Alimak Group AB (publ)
F:2GP
|
SE |
|
Bc Technology Group Ltd
F:9D2
|
CN |
|
Getchell Gold Corp
F:GGA1
|
CA |
|
I
|
InZinc Mining Ltd
XBER:32L
|
CA |
|
S
|
Solaris Oilfield Infrastructure Inc
F:68S
|
US |
|
U
|
Upland Resources Ltd
F:2UZ
|
JE |
|
G
|
Glanbia PLC
LSE:GLB
|
IE |
|
A
|
Altium Ltd
OTC:ALMFF
|
AU |
|
Toleranzia AB
F:0EH
|
SE |
|
F
|
Fireweed Zinc Ltd
F:20F
|
CA |
|
Crimson Tide PLC
F:EYM
|
UK |
|
K
|
Kapsch Trafficcom AG
XMUN:BZ6
|
AT |
Wall St Price Targets
6IB Price Targets Summary
Innovent Biologics Inc
According to Wall Street analysts, the average 1-year price target for 6IB is 11.199 EUR with a low forecast of 8.353 EUR and a high forecast of 13.805 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 6IB's stock price target?
Price Target
11.199
EUR
According to Wall Street analysts, the average 1-year price target for 6IB is 11.199 EUR with a low forecast of 8.353 EUR and a high forecast of 13.805 EUR.
What is the Revenue forecast for Innovent Biologics Inc?
Projected CAGR
20%
Over the last 8 years, the compound annual growth rate for Revenue has been 127%. The projected CAGR for the next 8 years is 20%.
What is the Gross Profit forecast for Innovent Biologics Inc?
Projected CAGR
20%
The compound annual growth rate for Gross Profit over the next 8 years is 20%.
What is the Operating Income forecast for Innovent Biologics Inc?
Projected CAGR
44%
The compound annual growth rate for Operating Income over the next 8 years is 44%.
What is the Pre-Tax Income forecast for Innovent Biologics Inc?
Projected CAGR
90%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 90%.
What is the Net Income forecast for Innovent Biologics Inc?
Projected CAGR
36%
The compound annual growth rate for Net Income over the next 8 years is 36%.
